NASDAQ:BBOT BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis $4.78 -0.11 (-2.15%) As of 03:56 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About BridgeBio Oncology Therapeutics Stock (NASDAQ:BBOT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BBOT alerts:Sign Up Key Stats Today's Range$4.71▼$4.9950-Day Range$4.88▼$9.6052-Week Range$4.71▼$14.87Volume614,428 shsAverage Volume383,383 shsMarket Capitalization$382.81 millionP/E RatioN/ADividend YieldN/APrice Target$22.88Consensus RatingModerate Buy Company Overview BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company seeks to address cancer-driving alterations that may be underserved by existing treatments, using targeted therapies designed to match the molecular characteristics of individual tumors. Its pipeline includes BBO-8520, an investigational KRAS G12C inhibitor designed to target both active and inactive forms of the KRAS G12C protein. The program is being evaluated for potential use in cancers such as non-small cell lung cancer and other solid tumors harboring KRAS G12C mutations. BridgeBio Oncology Therapeutics is also advancing additional targeted oncology programs, including therapies directed at other genetically defined cancer pathways. The company is part of the broader BridgeBio organization and conducts drug discovery and development activities in the United States. As a clinical-stage business, its operations are primarily focused on research, clinical testing, regulatory development and establishing partnerships or other arrangements that may support the future development and commercialization of its oncology candidates.AI Generated. May Contain Errors. Read More BridgeBio Oncology Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreBBOT MarketRank™: BridgeBio Oncology Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 370th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBridgeBio Oncology Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialBridgeBio Oncology Therapeutics has a consensus price target of $22.88, representing about 367.8% upside from its current price of $4.89.Amount of Analyst CoverageBridgeBio Oncology Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BridgeBio Oncology Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BridgeBio Oncology Therapeutics are expected to grow in the coming year, from ($2.79) to ($2.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Oncology Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Oncology Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBridgeBio Oncology Therapeutics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.22% of the float of BridgeBio Oncology Therapeutics has been sold short.Short Interest Ratio / Days to CoverBridgeBio Oncology Therapeutics has a short interest ratio ("days to cover") of 20.77, which indicates bearish sentiment.Change versus previous monthShort interest in BridgeBio Oncology Therapeutics has recently increased by 6.63%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBridgeBio Oncology Therapeutics does not currently pay a dividend.Dividend GrowthBridgeBio Oncology Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.10 News SentimentBridgeBio Oncology Therapeutics has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for BridgeBio Oncology Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for BBOT on MarketBeat in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BridgeBio Oncology Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.40% of the stock of BridgeBio Oncology Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.89% of the stock of BridgeBio Oncology Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Oncology Therapeutics' insider trading history. Receive BBOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Oncology Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBOT Stock News HeadlinesBridgeBio Oncology Therapeutics consensus price target cut by 13.05% to $22.55September 15 at 2:11 PM | msn.comBridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS PlaybookSeptember 12, 2026 | finance.yahoo.com$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal.September 16 at 1:00 AM | American Alternative (Ad)BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sets New 52-Week Low After Analyst DowngradeSeptember 12, 2026 | americanbankingnews.comBridgeBio Oncology Therapeutics (NASDAQ:BBOT) Reaches New 52-Week Low Following Analyst DowngradeSeptember 12, 2026 | americanbankingnews.comLeerink Partners Issues Pessimistic Forecast for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock PriceSeptember 12, 2026 | americanbankingnews.comBridgeBio Oncology Therapeutics (NASDAQ:BBOT) Lowered to Strong Sell Rating by Wall Street ZenSeptember 12, 2026 | americanbankingnews.comWedbush Reiterates Outperform Rating for BridgeBio Oncology Therapeutics (NASDAQ:BBOT)September 11, 2026 | americanbankingnews.comSee More Headlines BBOT Stock Analysis - Frequently Asked Questions How have BBOT shares performed this year? BridgeBio Oncology Therapeutics' stock was trading at $11.50 at the beginning of 2026. Since then, BBOT shares have decreased by 57.5% and is now trading at $4.89. How were BridgeBio Oncology Therapeutics' earnings last quarter? BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) issued its quarterly earnings results on Tuesday, August, 11th. The company reported ($705.20) earnings per share for the quarter. Who are BridgeBio Oncology Therapeutics' major shareholders? Top institutional investors of BridgeBio Oncology Therapeutics include Wellington Management Group LLP (3.48%), Opaleye Management Inc. (0.87%), Tema ETFs LLC (0.12%) and Tidal Investments LLC (0.12%). How do I buy shares of BridgeBio Oncology Therapeutics? Shares of BBOT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today9/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 6 days, BBOT's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BBOT CIK1869105 Webwww.bridgebio.com Phone(857) 702-0377FaxN/AEmployees88Year Founded2025Price Target and Rating Average Price Target for BridgeBio Oncology Therapeutics$22.88 High Price Target$29.00 Low Price Target$15.00 Potential Upside/Downside+380.5%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$134.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-46.90% Return on Assets-42.17% Debt Debt-to-Equity RatioN/A Current Ratio4.69 Quick Ratio4.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.14 per share Price / Book0.93Miscellaneous Outstanding Shares80,170,000Free Float60,612,000Market Cap$381.69 million OptionableN/A Beta0.38 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:BBOT) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Oncology Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Oncology Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
